GB201813678D0 - Acylated calcitonin mimetics - Google Patents

Acylated calcitonin mimetics

Info

Publication number
GB201813678D0
GB201813678D0 GBGB1813678.8A GB201813678A GB201813678D0 GB 201813678 D0 GB201813678 D0 GB 201813678D0 GB 201813678 A GB201813678 A GB 201813678A GB 201813678 D0 GB201813678 D0 GB 201813678D0
Authority
GB
United Kingdom
Prior art keywords
acylated
calcitonin mimetics
calcitonin
mimetics
acylated calcitonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1813678.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KeyBioscience AG
Original Assignee
KeyBioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KeyBioscience AG filed Critical KeyBioscience AG
Priority to GBGB1813678.8A priority Critical patent/GB201813678D0/en
Publication of GB201813678D0 publication Critical patent/GB201813678D0/en
Priority to CN202610554181.5A priority patent/CN122464982A/zh
Priority to AU2019323697A priority patent/AU2019323697B2/en
Priority to CN202610554176.4A priority patent/CN122541545A/zh
Priority to CA3110033A priority patent/CA3110033A1/en
Priority to BR112021003088-3A priority patent/BR112021003088A2/pt
Priority to PE2021000229A priority patent/PE20211785A1/es
Priority to US17/270,331 priority patent/US20220380432A1/en
Priority to CN202511289422.XA priority patent/CN121021664A/zh
Priority to EP19765419.7A priority patent/EP3840774A1/en
Priority to CN201980055426.8A priority patent/CN112601542A/zh
Priority to KR1020257032307A priority patent/KR20250143876A/ko
Priority to IL280885A priority patent/IL280885B2/en
Priority to CN202511289522.2A priority patent/CN121226531A/zh
Priority to MX2021002072A priority patent/MX2021002072A/es
Priority to PCT/EP2019/072533 priority patent/WO2020039051A1/en
Priority to EA202190477A priority patent/EA202190477A1/ru
Priority to JP2021509906A priority patent/JP2021535119A/ja
Priority to KR1020217008022A priority patent/KR102866729B1/ko
Priority to ZA2021/00869A priority patent/ZA202100869B/en
Priority to PH12021550331A priority patent/PH12021550331A1/en
Priority to CL2021000427A priority patent/CL2021000427A1/es
Priority to CONC2021/0002071A priority patent/CO2021002071A2/es
Priority to JP2024193478A priority patent/JP2025023996A/ja
Priority to AU2025205152A priority patent/AU2025205152A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
GBGB1813678.8A 2018-08-22 2018-08-22 Acylated calcitonin mimetics Ceased GB201813678D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB1813678.8A GB201813678D0 (en) 2018-08-22 2018-08-22 Acylated calcitonin mimetics
KR1020217008022A KR102866729B1 (ko) 2018-08-22 2019-08-22 아실화된 칼시토닌 모방체
IL280885A IL280885B2 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics
MX2021002072A MX2021002072A (es) 2018-08-22 2019-08-22 Mimeticos de calcitonina acilados.
CN202610554176.4A CN122541545A (zh) 2018-08-22 2019-08-22 酰化的降钙素模拟物
CA3110033A CA3110033A1 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics
BR112021003088-3A BR112021003088A2 (pt) 2018-08-22 2019-08-22 miméticos de calcitonina acilados
PE2021000229A PE20211785A1 (es) 2018-08-22 2019-08-22 Mimeticos de calcitonina acilados
US17/270,331 US20220380432A1 (en) 2018-08-22 2019-08-22 Acylated Calcitonin Mimetics
CN202511289422.XA CN121021664A (zh) 2018-08-22 2019-08-22 酰化的降钙素模拟物
EP19765419.7A EP3840774A1 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics
CN201980055426.8A CN112601542A (zh) 2018-08-22 2019-08-22 酰化的降钙素模拟物
KR1020257032307A KR20250143876A (ko) 2018-08-22 2019-08-22 아실화된 칼시토닌 모방체
CN202610554181.5A CN122464982A (zh) 2018-08-22 2019-08-22 酰化的降钙素模拟物
CN202511289522.2A CN121226531A (zh) 2018-08-22 2019-08-22 酰化的降钙素模拟物
AU2019323697A AU2019323697B2 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics
PCT/EP2019/072533 WO2020039051A1 (en) 2018-08-22 2019-08-22 Acylated calcitonin mimetics
EA202190477A EA202190477A1 (ru) 2018-08-22 2019-08-22 Ацилированные миметики кальцитонина
JP2021509906A JP2021535119A (ja) 2018-08-22 2019-08-22 アシル化カルシトニン模倣体
ZA2021/00869A ZA202100869B (en) 2018-08-22 2021-02-09 Acylated calcitonin mimetics
PH12021550331A PH12021550331A1 (en) 2018-08-22 2021-02-16 Acylated calcitonin mimetics
CL2021000427A CL2021000427A1 (es) 2018-08-22 2021-02-19 Miméticos de calcitonina acilados
CONC2021/0002071A CO2021002071A2 (es) 2018-08-22 2021-02-22 Miméticos de calcitonina acilados
JP2024193478A JP2025023996A (ja) 2018-08-22 2024-11-05 アシル化カルシトニン模倣体
AU2025205152A AU2025205152A1 (en) 2018-08-22 2025-07-04 Acylated calcitonin mimetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1813678.8A GB201813678D0 (en) 2018-08-22 2018-08-22 Acylated calcitonin mimetics

Publications (1)

Publication Number Publication Date
GB201813678D0 true GB201813678D0 (en) 2018-10-03

Family

ID=63668212

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1813678.8A Ceased GB201813678D0 (en) 2018-08-22 2018-08-22 Acylated calcitonin mimetics

Country Status (18)

Country Link
US (1) US20220380432A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840774A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021535119A (cg-RX-API-DMAC7.html)
KR (2) KR20250143876A (cg-RX-API-DMAC7.html)
CN (5) CN121226531A (cg-RX-API-DMAC7.html)
AU (2) AU2019323697B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003088A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110033A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000427A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021002071A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190477A1 (cg-RX-API-DMAC7.html)
GB (1) GB201813678D0 (cg-RX-API-DMAC7.html)
IL (1) IL280885B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002072A (cg-RX-API-DMAC7.html)
PE (1) PE20211785A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550331A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020039051A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100869B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN118684757A (zh) * 2023-03-24 2024-09-24 成都奥达生物科技有限公司 一种长效降钙素类似物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU742270B2 (en) 1997-04-16 2001-12-20 Enteris Biopharma, Inc. Direct expression of peptides into culture media
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1608347B1 (en) 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
JP4829783B2 (ja) * 2003-06-24 2011-12-07 バイオコン・リミテッド カルシトニン薬−オリゴマーコンジュゲートの混合物および疼痛治療における使用方法
PT2316473E (pt) 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
AU2004317954A1 (en) 2003-09-17 2005-10-13 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
JP2008506750A (ja) 2004-07-22 2008-03-06 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー チオール基を含む化合物の排出ポンプ抑制剤としての使用
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PT1834635E (pt) 2006-03-13 2011-10-13 Advanced In Vitro Cell Technologies S L Sistemas estáveis de nanocápsula para a administração de moléculas activas
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2405934B1 (en) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
WO2011051312A1 (en) * 2009-10-30 2011-05-05 Novo Nordisk A/S Derivatives of cgrp
JP6231386B2 (ja) * 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
SI3095484T1 (en) * 2011-11-02 2018-08-31 Keybioscience Ag Calcitonin mimetics for the treatment of diseases and disorders
US9533022B2 (en) * 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
CA2854175A1 (en) * 2011-11-02 2013-05-10 Keybioscience Ag Peptide analogs for treating diseases and disorders
BR112016010643A2 (pt) * 2013-11-14 2017-12-05 Keybioscience Ag peptídeo
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EP3359181A1 (en) * 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
KR102444366B1 (ko) * 2016-06-03 2022-09-19 케모센트릭스, 인크. 간 섬유화 치료 방법

Also Published As

Publication number Publication date
JP2021535119A (ja) 2021-12-16
BR112021003088A2 (pt) 2021-05-11
CN121226531A (zh) 2025-12-30
IL280885A (en) 2021-04-29
US20220380432A1 (en) 2022-12-01
IL280885B2 (en) 2024-11-01
CN122464982A (zh) 2026-07-28
EP3840774A1 (en) 2021-06-30
JP2025023996A (ja) 2025-02-19
CO2021002071A2 (es) 2021-03-08
AU2019323697A1 (en) 2021-03-04
EA202190477A1 (ru) 2021-06-04
AU2019323697B2 (en) 2025-08-07
MX2021002072A (es) 2021-04-28
KR20210047322A (ko) 2021-04-29
WO2020039051A1 (en) 2020-02-27
ZA202100869B (en) 2022-09-28
CN112601542A (zh) 2021-04-02
KR102866729B1 (ko) 2025-10-02
PH12021550331A1 (en) 2021-10-04
AU2025205152A1 (en) 2025-07-24
PE20211785A1 (es) 2021-09-09
CL2021000427A1 (es) 2021-08-20
CN121021664A (zh) 2025-11-28
IL280885B1 (en) 2024-07-01
CN122541545A (zh) 2026-08-11
CA3110033A1 (en) 2020-02-27
KR20250143876A (ko) 2025-10-02

Similar Documents

Publication Publication Date Title
ZA202100869B (en) Acylated calcitonin mimetics
IL276752B1 (en) Bottle assembly
SG11202101391WA (en) Recombinant lectin variants
GB201912107D0 (en) Combination
ZA202100056B (en) Handheld aesthesiometer
PL3626317T3 (pl) Bramka
GB201807046D0 (en) Combination
GB201914847D0 (en) Combination
HK40056341A (en) Acylated calcitonin mimetics
GB201914849D0 (en) Microsphere-drug combination
GB201913068D0 (en) Combination
HUE058119T2 (hu) Kézi eszteziométer
ZA201905705B (en) Dispensing arrangement
GB2575441B (en) Addressing mechanism
GB201820913D0 (en) St
GB201900555D0 (en) Concept one
GB201813992D0 (en) St
GB201813486D0 (en) st
GB201813476D0 (en) st
GB201813347D0 (en) St
GB201813206D0 (en) St
ZAF201801202S (en) Construction units
ZAF201801201S (en) Construction units
GB201811251D0 (en) St
GB201811625D0 (en) Concept One

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)